Curaleaf Holdings (CURLF) Asset Writedowns and Impairment (2021 - 2025)

Curaleaf Holdings (CURLF) posted quarterly Asset Writedowns and Impairment of $4.3 million for Q4 2025, up 481.84% year-on-year from $740922.4 in Q4 2024, and up 608.37% on a QoQ basis from -$848000.0 in Q3 2025.

Curaleaf Holdings (CURLF) Asset Writedowns and Impairment (2021 - 2025) Analysis & Trends

Curaleaf Holdings (CURLF) has reported Asset Writedowns and Impairment for 5 consecutive years, with $4.3 million the latest figure, recorded in Q4 2025.

  • Quarterly Asset Writedowns and Impairment rose 481.84% year-over-year to $4.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.7 million (down 58.98% YoY) and the FY2025 annual result came in at $977000.0, up 135.99% from the prior year.
  • Asset Writedowns and Impairment climbed to $4.3 million in Q4 2025 per CURLF's latest filing, from -$848000.0 in the prior quarter.
  • Over the last five years, Asset Writedowns and Impairment for CURLF reached as high as $116.9 million in Q4 2022 and fell as low as -$1.1 million in Q4 2024.
  • A 5-year average of $16.7 million and a median of $2.0 million in 2023 frame the typical range for Asset Writedowns and Impairment.
  • Annual changes were most pronounced in 2022 — Asset Writedowns and Impairment jumped 1170.42% — and 2024, when it slumped 118.22%.
  • Year by year, Asset Writedowns and Impairment stood at $9.2 million in 2021, then soared by 1170.42% to $116.9 million in 2022, then tumbled by 94.7% to $6.2 million in 2023, then slumped by 118.22% to -$1.1 million in 2024, then surged by 481.84% to $4.3 million in 2025.
  • According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $4.3 million, -$848000.0, and -$1.1 million for Q4 2025, Q3 2025, and Q4 2024 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 89.51 Bn 87.64 Bn -
2 Teva Pharmaceutical Industries 35.95 Bn 32.21 Bn 1.97 Bn
3 Zoetis 32.59 Bn 30.65 Bn 1.62 Bn
4 Takeda Pharmaceutical 27.51 Bn 23.45 Bn 4.39 Bn
5 United Therapeutics 23.06 Bn 20.91 Bn 648.10 Mn
6 RedHill Biopharma 21.48 Bn 21.48 Bn -
7 Viatris 20.25 Bn 18.44 Bn 1.16 Bn
8 Neurocrine Biosciences 17.79 Bn 16.48 Bn 800.70 Mn
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn
10 Curaleaf Holdings 6.98 Bn 6.98 Bn 157.29 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 4.31 Mn
Dec 31, 2025 4.31 Mn
Sep 30, 2025 -848,000.00
Sep 30, 2025 -848,000.00
Dec 31, 2024 -1.13 Mn
Dec 31, 2024 -1.13 Mn
Sep 30, 2024 -642,000.00
Sep 30, 2024 -642,000.00
Dec 31, 2023 6.20 Mn
Dec 31, 2023 6.20 Mn
Sep 30, 2023 -301,000.00
Sep 30, 2023 -301,000.00
Dec 31, 2022 116.88 Mn
Dec 31, 2022 116.88 Mn
Dec 31, 2021 9.20 Mn
Dec 31, 2021 9.20 Mn